Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) closed at $1.05 up 1.15% from its previous closing price of $1.04. In other words, the price has increased by $1.15 from its previous closing price. On the day, 77330.0 shares were traded. CYCC stock price reached its highest trading level at $1.052 during the session, while it also had its lowest trading level at $1.0.
Ratios:
For a deeper understanding of Cyclacel Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.07 and its Current Ratio is at 1.07. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 21 ’23 when McBarron Paul bought 1,886 shares for $3.31 per share. The transaction valued at 6,252 led to the insider holds 33,378 shares of the business.
Rombotis Spiro George bought 6,070 shares of CYCC for $20,122 on Dec 21 ’23. The President and CEO now owns 68,658 shares after completing the transaction at $3.31 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYCC now has a Market Capitalization of 2076858 and an Enterprise Value of -3918137. For the stock, the TTM Price-to-Sale (P/S) ratio is 25.91 while its Price-to-Book (P/B) ratio in mrq is 1.90. Its current Enterprise Value per Revenue stands at -48.977 whereas that against EBITDA is 0.194.
Stock Price History:
Over the past 52 weeks, CYCC has reached a high of $11.34, while it has fallen to a 52-week low of $0.95. The 50-Day Moving Average of the stock is -30.89%, while the 200-Day Moving Average is calculated to be -55.73%.
Shares Statistics:
For the past three months, CYCC has traded an average of 132.08K shares per day and 53750 over the past ten days. A total of 1.97M shares are outstanding, with a floating share count of 1.85M. Insiders hold about 6.08% of the company’s shares, while institutions hold 11.62% stake in the company. Shares short for CYCC as of 1723680000 were 54318 with a Short Ratio of 0.41, compared to 1721001600 on 113128. Therefore, it implies a Short% of Shares Outstanding of 54318 and a Short% of Float of 2.87.
